Overview
This entry refers to the symptomatic form of fragile X syndrome that can occur in women who carry a change (mutation) in the FMR1 gene on the X chromosome. Fragile X syndrome is the most common inherited cause of intellectual disability. While it is often thought of as mainly affecting boys and men, women who carry the full mutation in the FMR1 gene can also show symptoms, though these are usually milder and more variable than in males. This happens because women have two X chromosomes, and the normal copy can partially compensate for the affected one — but this compensation varies from person to person depending on a process called X-inactivation. Women with the symptomatic form may experience learning difficulties, attention problems, anxiety, social shyness, and sometimes mild intellectual disability. Some may have subtle physical features such as a long face or prominent ears, though these are less noticeable than in affected males. Emotional and behavioral challenges, including mood swings and depression, are also common. Note that this Orphanet entry is marked as 'OBSOLETE,' meaning it has been retired or merged into broader fragile X syndrome classifications. However, the clinical reality remains: female carriers of the full FMR1 mutation can and do experience meaningful symptoms. Treatment is supportive and may include speech therapy, behavioral therapy, educational support, and medications for anxiety or attention difficulties. There is currently no cure, but early intervention can significantly improve quality of life.
Key symptoms:
Learning difficultiesAttention problems or ADHD-like symptomsAnxietySocial shyness or social anxietyMild intellectual disabilityDifficulty with math and spatial reasoningDepression or mood swingsLong faceProminent earsDifficulty with executive function (planning and organizing)Speech and language delaysSensory sensitivitiesJoint flexibility or hypermobility
X-linked dominant
Carried on the X chromosome; a single copy can cause the condition
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Symptomatic form of fragile X syndrome in female carriers.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for OBSOLETE: Symptomatic form of fragile X syndrome in female carriers at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Symptomatic form of fragile X syndrome in female carriers.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Symptomatic form of fragile X syndrome in female carriers.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Symptomatic form of fragile X syndrome in female carriers.
Start the conversation →Latest news about OBSOLETE: Symptomatic form of fragile X syndrome in female carriers
No recent news articles for OBSOLETE: Symptomatic form of fragile X syndrome in female carriers.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is the FMR1 mutation in my case, and what does that mean for my symptoms?,What educational or workplace accommodations would you recommend?,Should I see a psychologist or psychiatrist for my anxiety or attention difficulties?,What are the chances I could pass this condition to my children?,Should other family members be tested for the FMR1 gene change?,Are there any clinical trials or new treatments I should know about?,How often should I have follow-up appointments, and with which specialists?
Common questions about OBSOLETE: Symptomatic form of fragile X syndrome in female carriers
What is OBSOLETE: Symptomatic form of fragile X syndrome in female carriers?
This entry refers to the symptomatic form of fragile X syndrome that can occur in women who carry a change (mutation) in the FMR1 gene on the X chromosome. Fragile X syndrome is the most common inherited cause of intellectual disability. While it is often thought of as mainly affecting boys and men, women who carry the full mutation in the FMR1 gene can also show symptoms, though these are usually milder and more variable than in males. This happens because women have two X chromosomes, and the normal copy can partially compensate for the affected one — but this compensation varies from person
How is OBSOLETE: Symptomatic form of fragile X syndrome in female carriers inherited?
OBSOLETE: Symptomatic form of fragile X syndrome in female carriers follows a x-linked dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does OBSOLETE: Symptomatic form of fragile X syndrome in female carriers typically begin?
Typical onset of OBSOLETE: Symptomatic form of fragile X syndrome in female carriers is childhood. Age of onset can vary across affected individuals.